Offer - Urjas Oil for just ₹ 1 X
Lobet Tablet is a commercial drug that is prescribed in the form of Tablet. High BP are some of its major therapeutic uses. Other than this, Lobet Tablet has some other therapeutic uses, which have been discussed ahead.
The optimal dosage of Lobet Tablet is largely dependent on the individual's body weight, medical history, gender and age. Individual symptoms and route of administration also determines the right dosage. This information has been provided in detail in the dosage section.
Some other side effects of Lobet Tablet have been listed ahead. Normally, these side effects of Lobet Tablet are not long lasting and go away when the treatment is finished. However, if these continue for a longer time, consult your doctor right away.
Furthermore, you should know that effect of Lobet Tablet is Severe for pregnant women and Mild for women who are breastfeeding. It is important to know if Lobet Tablet has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Lobet Tablet related warnings section.
Lobet Tablet is not recommended if you suffer from certain medical conditions as it can have adverse effects. Diabetes, Asthma, COPD (Chronic Obstructive Pulmonary Disease) are examples of such conditions. Some other conditions that can be affected by Lobet Tablet are listed in the contraindications section below.
Besides this, Lobet Tablet may also have severe interaction with some medicines. See below for a complete list.
In addition to these precautions, you may also note that Lobet Tablet is not safe while driving, and is is not addictive in nature.
Lobet Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Geriatric |
|
Adult |
|
Is the use of Lobet Tablet safe for pregnant women?
Lobet (Sam) has many dangerous side effects in pregnant women. If you are pregnant, do not consume Lobet (Sam) without medical advice.
Is the use of Lobet Tablet safe during breastfeeding?
Breastfeeding women can take Lobet (Sam) as it bears very minor side effects for them.
What is the effect of Lobet Tablet on the Kidneys?
Using Lobet (Sam) does not have any harmful effects on kidneys.
What is the effect of Lobet Tablet on the Liver?
Lobet (Sam) has very mild side effects on the liver.
What is the effect of Lobet Tablet on the Heart?
Side effects of Lobet (Sam) rarely affect the heart.
Lobet Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Moderate
If you are suffering from any of the following diseases, you should not take Lobet Tablet unless your doctor advises you to do so -
Is this Lobet Tablet habit forming or addictive?
Lobet Tablet does not cause addiction.
Is it safe to drive or operate heavy machinery when consuming?
You may feel sleepy or tired after taking Lobet Tablet . So it is best to avoid driving.
Is it safe?
Yes, Lobet Tablet is safe but you must consult your doctor before taking it.
Is it able to treat mental disorders?
There is no benefit of taking Lobet Tablet for mental disorders.
Interaction between Food and Lobet Tablet
Lobet Tablet may take longer to act if you eat some foods while taking it. Follow your doctor's advice on this.
Interaction between Alcohol and Lobet Tablet
Taking alcohol with Lobet Tablet can be dangerous.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Trandate® (labetalol hydrochloride)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 151
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 735-737